ESMO Breast Cancer is an annual congress taking place for the first time on 2-4 May 2019 in Berlin, Germany. Brought to you by ESMO, your trusted provider of specialised education in oncology.
GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.
Our Paper about PIK3CA-Mutations is one of the most-cited papers in JCO.
Our paper on mutations analysis in the Geparsixto TNBC-Arm was discussed at ASCO-News.
Palbociclib Combined with Fulvestrant in PremenopausalWomen with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
Prof. Loibl and Prof. Denkert discuss "How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?" in the current JCO Editorial.
GBG Forschungs GmbHMartin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440
+49 6102 7480-0 | nfGBGd